Quantcast

Latest Merck Stories

2014-01-28 16:26:04

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 LAPLACE-2 (LDL-C Assessment with PCSK9 MonoclonaL Antibody Inhibition Combined with Statin ThErapy-2) trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week...

2014-01-23 08:31:51

Study Meets Co-Primary Endpoints of LDL Cholesterol Reduction THOUSAND OAKS, Calif., Jan. 23, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 GAUSS-2 (Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-2) trial evaluating evolocumab in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 12 and the...

2014-01-20 08:23:19

CAMBRIDGE, Massachusetts and LONDON, January 20, 2014 /PRNewswire/ -- Appoints Pierre Dodion as an Associate Partner Alacrita [http://www.alacritaconsulting.com ], the transatlantic life sciences consulting firm, today announced that it has appointed Pierre Dodion as an Associate Partner based in its Cambridge, MA office. Pierre was formerly SVP, Corporate Development and Operations at ARIAD Pharmaceuticals and played a major role in ARIAD's expansion into Europe and...

2014-01-14 16:25:04

COPENHAGEN, Denmark, January 14, 2014 /PRNewswire/ -- Symphogen A/S, a private biopharmaceutical company with leadership in recombinant antibody mixtures for therapeutic use, today presented its achievements in 2013 and outlook for 2014 at JP Morgan's 32nd Annual Healthcare Conference in San Francisco, California. The presentation was made by Kirsten Drejer, CEO. Pipeline update Symphogen has continued to expand its oncology pipeline to include projects that...

2014-01-12 23:01:32

The Firm is representing plaintiffs in Fosamax lawsuits that allege use of the drug caused patients to sustain painful and debilitating femur fractures New York, NY (PRWEB) January 12, 2014 Thousands of Fosamax lawsuits (http://www.consumerinjurylawyers.com/fosamax/Fosamax-Femur-Fracture-Lawsuits.html) filed on behalf of women who sustained femur fractures, allegedly due to their use of the medication, continue to move forward in state and federal courts throughout the country,...

2014-01-11 23:00:17

http://www.DrugNews.net is the web’s premier source for prescription device warnings, research, side effects and legal news. Visit the DrugNews Center today. Chicago, IL (PRWEB) January 11, 2014 The birth control resource center at DrugNews.net has added new information for those patients using the contraceptive NuvaRing. The maker of the device, Merck, recently challenged another company’s plans to market a generic version in upcoming years*. DrugNews is a patient resource center...

2014-01-09 08:26:35

-Mitchell Seyedin, Ph.D., to serve as Executive Chairman in newly created role- ST. LOUIS, Jan. 9, 2014 /PRNewswire/ -- ISTO Technologies, Inc., a privately-held orthobiological regenerative medicine company, announced today that George W. Dunbar, Jr., a well-recognized senior executive with over 25 years' experience in the field of life sciences, was appointed President and Chief Executive Officer, effective immediately. Mitchell Seyedin, Ph.D., will continue to serve the Company...

2014-01-09 08:26:30

Revenue Growth of 12%-14% Expected Year-over-Year BOSTON, Jan. 9, 2014 /PRNewswire/ -- Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced preliminary, unaudited financial results of the fourth quarter and year ended December 31, 2013. For the fourth quarter of 2013, the Company expects to report: -- Total revenues in the range of $7.4 to $8.0 million, as compared with $7.1 million in the fourth quarter of 2012. -- Services revenues from Molecular Profiles in the...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.